
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing erythromycin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing erythromycin are listed in tablet, capsule, suspension, granule for suspension, powder for suspension and injection forms, and as gels, solutions and swabs for the skin and ointments for the eye. None of the FDA-approved erythromycin solutions is for oral use. It is also a component of FDA-approved kits.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Erythromycin is a macrolide antibiotic that compounding pharmacies prepare as oral suspensions and as topical solutions, gels and creams.
Erythromycin is a macrolide antibiotic. It binds the 50S subunit of the bacterial ribosome and blocks protein synthesis, so susceptible bacteria stop multiplying; it also stimulates motilin receptors in the gut, which speeds stomach emptying. Manufactured products include erythromycin tablets, USP, delayed-release capsules, E.E.S. ethylsuccinate suspension, Erythrocin lactobionate injection, an ophthalmic ointment, and topical solutions and gels. The oral label lists indications including mild to moderate respiratory tract infections, skin and skin structure infections, pertussis, Chlamydia trachomatis infections, and prevention of rheumatic fever recurrence in penicillin-allergic patients; the topical solution is FDA-approved for acne vulgaris. Prescribers may order erythromycin compounded when they want a topical strength or vehicle that is not manufactured, an oral liquid in a different base, or a combination with another active in a strength or base not manufactured. Compounded erythromycin preparations are not FDA-approved and require a prescription.
Erythromycin labels carry no boxed warning. The oral label warns of QT prolongation and torsades de pointes, liver injury including hepatitis, and Clostridioides difficile diarrhea, which can appear more than two months after a course. Erythromycin inhibits the liver enzyme CYP3A4 and is contraindicated with lovastatin, simvastatin, ergotamine, dihydroergotamine, pimozide and cisapride; it also raises levels of warfarin, digoxin, theophylline, carbamazepine, cyclosporine, colchicine, sildenafil and verapamil. People with a known long QT interval, uncorrected low potassium or magnesium, or a macrolide allergy should not use it; tell your prescriber about liver disease or myasthenia gravis. Observational studies have reported cardiovascular malformations after first trimester exposure. LactMed considers erythromycin acceptable during breastfeeding; watch the infant for diarrhea, thrush or irritability. For stomach upset, talk to your prescriber or pharmacist; seek care right away for rash, yellow eyes, dark urine, an irregular heartbeat, trouble breathing or severe watery diarrhea.
Erythromycin is bacteriostatic; it binds 23S rRNA within the 50S subunit and blocks peptide chain elongation. The base is acid-labile, so oral products rely on film or enteric coatings, esters or stable salts, and absorption varies between patients and is highest when fasting. Half-life is about 1.5 to 2 hours, plasma protein binding is high, metabolism is hepatic demethylation via CYP3A4, and excretion is mainly biliary with less than 5 percent of a dose recovered in active form in urine; it is not removed by dialysis. Labeled indications for erythromycin tablets, USP include upper and lower respiratory tract infections, skin and skin structure infections, pertussis, diphtheria (adjunct to antitoxin), erythrasma, intestinal amebiasis, chlamydial infections, nongonococcal urethritis, primary syphilis in penicillin allergy, Legionnaires' disease and rheumatic fever prophylaxis; erythromycin topical solution (Padagis) is labeled for acne vulgaris. Prescribers have ordered compounded oral erythromycin as a prokinetic for gastroparesis, an off-label use described in StatPearls. Dosing is per prescriber. Monitoring: liver function tests, QTc in patients with cardiac disease or on interacting drugs, electrolytes in high-risk patients, and emergence of resistance with long-term prokinetic use. Erythromycin is not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally